Mitochondrial dysfunction in the pathophysiology of bipolar disorder: Effects of pharmacotherapy

Mini-Reviews in Medicinal Chemistry

Volumn 15, Issue 5, 2015, Pages 355-365

  Callaly, Edward ^a   Walder, Ken ^a   Morris, Gerwyn ^e   Maes, Michael ^a,b,c   Debnath, Monojit ^d   Berk, Michael ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c STATE UNIVERSITY OF LONDRINA   (Brazil)

^d NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^e NONE

Author keywords

Bipolar disorder; Mitochondria; Mood stabiliser; Neuroprogression; Oxidative stress

Indexed keywords

N ACETYLASPARTIC ACID; UBIDECARENONE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; NITRIC OXIDE; TRANQUILIZER;

ARTICLE; BIPOLAR DISORDER; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON TRANSPORT; ENERGY METABOLISM; ENERGY YIELD; EXCITOTOXICITY; GENE EXPRESSION; GLYCOLYSIS; HUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; BRAIN; CALCIUM SIGNALING; GLIA; METABOLISM; MITOCHONDRION;

ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN; CALCIUM SIGNALING; ENERGY METABOLISM; HUMANS; MITOCHONDRIA; NEUROGLIA; NITRIC OXIDE; OXIDATIVE STRESS;

EID: 84928954768     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557515666150324122026     Document Type: Article

References (156)

1. Merikangas, K. R.; Jin, R.; He, J.-P.; Kessler, R. C.; Lee, S.; Sampson, N. A.; Viana, M. C.; Andrade, L. H.; Hu, C.; Karam, E. G.; Ladea, M.; Medina-Mora, M. E.; Ono, Y.; Posada-Villa, J.; Sagar, R.; Wells, J. E.; Zarkov, Z., Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch. Gen. Psychiatry, 2011, 68(3), 241-251.
2. Rihmer, Z.; Kiss, K., Bipolar disorders and suicidal behaviour. Bipolar Disord., 2002, 4 Suppl 1, 21-5.
3. Kato, T.; Kato, N., Mitochondrial dysfunction in bipolar disorder. Bipolar Disord., 2000, 2(3 Pt 1), 180-190.
4. Cataldo, A. M.; McPhie, D. L.; Lange, N. T.; Punzell, S.; Elmiligy, S.; Ye, N. Z.; Froimowitz, M. P.; Hassinger, L. C.; Menesale, E. B.; Sargent, L. W.; Logan, D. J.; Carpenter, A. E.; Cohen, B. M., Abnormalities in mitochondrial structure in cells from patients with bipolar disorder. Am. J. Pathol., 2010, 177(2), 575-585.
5. Iwamoto, K.; Bundo, M.; Kato, T., Altered expression of mitochondria-related genes in postmortem brains of patients with bipolar disorder or schizophrenia, as revealed by large-scale DNA microarray analysis. Hum. Mol. Genet., 2005, 14(2), 241-253.
6. Sun, X.; Wang, J. F.; Tseng, M.; Young, L. T., Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder. J. Psychiatry Neurosci., 2006, 31(3), 189-96.
7. Konradi, C.; Eaton, M.; MacDonald, M. L.; Walsh, J.; Benes, F. M.; Heckers, S., Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch. Gen. Psychiatry, 2004, 61(3), 300-8.
8. Berk, M.; Kapczinski, F.; Andreazza, A. C.; Dean, O. M.; Giorlando, F.; Maes, M.; Yücel, M.; Gama, C. S.; Dodd, S.; Dean, B.; Magalhães, P. V. S.; Amminger, P.; McGorry, P.; Malhi, G. S., Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev., 2011, 35(3), 804-817.
9. Moylan, S.; Berk, M.; Dean, O. M.; Samuni, Y.; Williams, L. J.; O'Neil, A.; Hayley, A. C.; Pasco, J. A.; Anderson, G.; Jacka, F. N.; Maes, M., Oxidative & nitrosative stress in depression: why so much stress? Neurosci. Biobehav. Rev., 2014, 45, 46-62.
10. Wang, J.-F.; Shao, L.; Sun, X.; Young, L. T., Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord., 2009, 11(5), 523-529.
11. Dager, S. R.; Friedman, S. D.; Parow, A.; Demopulos, C.; Stoll, A. L.; Lyoo, I. K.; Dunner, D. L.; Renshaw, P. F., Brain metabolic alterations in medication-free patients with bipolar disorder. Arch. Gen. Psychiatry, 2004, 61(5), 450-458.
12. Regenold, W. T.; Phatak, P.; Marano, C. M.; Sassan, A.; Conley, R. R.; Kling, M. A., Elevated Cerebrospinal Fluid Lactate Concentrations in Patients with Bipolar Disorder and Schizophrenia: Implications for the Mitochondrial Dysfunction Hypothesis. Biol. Psychiatry, 2009, 65(6), 489-494.
13. Kato, T.; Takahashi, S.; Shioiri, T.; Inubushi, T., Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo 31P and 7Li magnetic resonance spectroscopy. J. Affect. Disord., 1993, 27(1), 53-59.
14. Kato, T.; Shioiri, T.; Murashita, J.; Hamakawa, H.; Inubushi, T.; Takahashi, S., Phosphorus-31 magnetic resonance spectroscopy and ventricular enlargement in bipolar disorder. Psychiatry Res., 1994, 55(1), 41-50.
15. Kato, T.; Murashita, J.; Kamiya, A.; Shioiri, T.; Kato, N.; Inubushi, T., Decreased brain intracellular pH measured by 31P-MRS in bipolar disorder: a confirmation in drug-free patients and correlation with white matter hyperintensity. Eur. Arch. Psychiatry Clin. Neurosci., 1998, 248(6), 301-306.
16. Hamakawa, H.; Murashita, J.; Yamada, N.; Inubushi, T.; Kato, N.; Kato, T., Reduced intracellular pH in the basal ganglia and whole brain measured by 31P-MRS in bipolar disorder. Psychiatry Clin. Neurosci., 2004, 58(1), 82-88.
17. Andreazza, A. C.; Shao, L.; Wang, J.-F.; Young, L. T., Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch. Gen. Psychiatry, 2010, 67(4), 360-368.
18. Wang, J.-F., Defects of mitochondrial electron transport chain in bipolar disorder: implications for mood-stabilizing treatment. Can. J. Psychiatry, 2007, 52(12), 753-762.
19. Kunz, M.; Gama, C. S.; Andreazza, A. C.; Salvador, M.; Ceresér, K. M.; Gomes, F. A.; Belmonte-de-Abreu, P. S.; Berk, M.; Kapczinski, F., Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(7), 1677-1681.
20. Munkholm, K.; Vinberg, M.; Berk, M.; Kessing, L. V., Staterelated alterations of gene expression in bipolar disorder: a systematic review. Bipolar Disord., 2012, 14(7), 684-696.
21. Malhi, G. S.; Ivanovski, B.; Hadzi-Pavlovic, D.; Mitchell, P. B.; Vieta, E.; Sachdev, P., Neuropsychological deficits and functional impairment in bipolar depression, hypomania and euthymia. Bipolar Disord., 2007, 9(1-2), 114-125.
22. Castillo, M.; Kwock, L.; Courvoisie, H.; Hooper, S. R., Proton MR spectroscopy in children with bipolar affective disorder: preliminary observations. AJNR. Am. J. Neuroradiol., 2000, 21(5), 832-838.
23. Michael, N.; Erfurth, A.; Ohrmann, P.; Gössling, M.; Arolt, V.; Heindel, W.; Pfleiderer, B., Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology(Berl.), 2003, 168(3), 344-346.
24. Singh, M.; Spielman, D.; Adleman, N.; Alegria, D.; Howe, M.; Reiss, A.; Chang, K., Brain glutamatergic characteristics of pediatric offspring of parents with bipolar disorder. Psychiatry Res., 2010, 182(2), 165-171.
25. Nery, F. G.; Stanley, J. A.; Chen, H.-H.; Hatch, J. P.; Nicoletti, M. A.; Monkul, E. S.; Lafer, B.; Soares, J. C., Bipolar disorder comorbid with alcoholism: a 1H magnetic resonance spectroscopy study. J. Psychiatr. Res., 2010, 44(5), 278-285.
26. Colla, M.; Schubert, F.; Bubner, M.; Heidenreich, J. O.; Bajbouj, M.; Seifert, F.; Luborzewski, A.; Heuser, I.; Kronenberg, G., Glutamate as a spectroscopic marker of hippocampal structural plasticity is elevated in long-term euthymic bipolar patients on chronic lithium therapy and correlates inversely with diurnal cortisol. Mol. Psychiatry, 2009, 14(7), 696.
27. Ongür, D.; Prescot, A. P.; Jensen, J. E.; Rouse, E. D.; Cohen, B. M.; Renshaw, P. F.; Olson, D. P., T2 relaxation time abnormalities in bipolar disorder and schizophrenia. Magn. Reson. Med., 2010, 63(1), 1-8.
28. Keinan, N.; Pahima, H.; Ben-Hail, D.; Shoshan-Barmatz, V., The role of calcium in VDAC1 oligomerization and mitochondria-mediated apoptosis. Biochim. Biophys. Acta, 2013, 1833(7), 1745-54.
29. Kato, T., Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. Cell Calcium, 2008, 44(1), 92-102.
30. Warsh, J. J.; Andreopoulos, S.; Li, P. P., Role of intracellular calcium signaling in the pathophysiology and pharmacotherapy of bipolar disorder: current status. Clin. Neurosci. Res., 2004, 4(3–4), 201-213.
31. Moreno, A.; Ross, B. D.; Bluml, S., Direct determination of the Nacetyl-L-aspartate synthesis rate in the human brain by(13)C MRS and [1-(13)C]glucose infusion. J. Neurochem., 2001, 77(1), 347-50.
32. Reynolds, L. M.; Reynolds, G. P., Differential regional Nacetylaspartate deficits in postmortem brain in schizophrenia, bipolar disorder and major depressive disorder. J. Psychiatr. Res., 2011, 45(1), 54-59.
33. Deicken, R. F.; Pegues, M. P.; Anzalone, S.; Feiwell, R.; Soher, B., Lower concentration of hippocampal N-acetylaspartate in familial bipolar I disorder. Am. J. Psychiatry, 2003, 160(5), 873-82.
34. Frye, M. A.; Thomas, M. A.; Yue, K.; Binesh, N.; Davanzo, P.; Ventura, J.; O'Neill, J.; Guze, B.; Curran, J. G.; Mintz, J., Reduced concentrations of N-acetylaspartate(NAA) and the NAA-creatine ratio in the basal ganglia in bipolar disorder: a study using 3-Tesla proton magnetic resonance spectroscopy. Psychiatry Res., 2007, 154(3), 259-265.
35. Murashita, J.; Kato, T.; Shioiri, T.; Inubushi, T.; Kato, N., Altered brain energy metabolism in lithium-resistant bipolar disorder detected by photic stimulated 31P-MR spectroscopy. Psychol. Med., 2000, 30(1), 107-115.
36. Kato, T.; Takahashi, S.; Shioiri, T.; Murashita, J.; Hamakawa, H.; Inubushi, T., Reduction of brain phosphocreatine in bipolar II disorder detected by phosphorus-31 magnetic resonance spectroscopy. J. Affect. Disord., 1994, 31(2), 125-133.
37. Chang, K.; Adleman, N.; Dienes, K.; Barnea-Goraly, N.; Reiss, A.; Ketter, T., Decreased N-Acetylaspartate in children with familial bipolar disorder. Biol. Psychiatry, 2003, 53(11), 1059-1065.
38. Winsberg, M. E.; Sachs, N.; Tate, D. L.; Adalsteinsson, E.; Spielman, D.; Ketter, T. A., Decreased dorsolateral prefrontal Nacetyl aspartate in bipolar disorder. Biol. Psychiatry, 2000, 47(6), 475-481.
39. Barbiroli, B.; Montagna, P.; Cortelli, P.; Iotti, S.; Lodi, R.; Barboni, P.; Monari, L.; Lugaresi, E.; Frassineti, C.; Zaniol, P., Defective brain and muscle energy metabolism shown by in vivo 31P magnetic resonance spectroscopy in nonaffected carriers of 11778 mtDNA mutation. Neurology, 1995, 45(7), 1364-1369.
40. Rango, M.; Bozzali, M.; Prelle, A.; Scarlato, G.; Bresolin, N., Brain activation in normal subjects and in patients affected by mitochondrial disease without clinical central nervous system involvement: a phosphorus magnetic resonance spectroscopy study. J. Cereb. Blood Flow Metab., 2001, 21(1), 85-91.
41. Lyoo, I. K.; Yoon, S.; Kim, T.-S.; Hwang, J.; Kim, J. E.; Won, W.; Bae, S.; Renshaw, P. F., A randomized, double-blind placebocontrolled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. Am. J. Psychiatry, 2012, 169(9), 937-945.
42. Rae, C.; Digney, A. L.; McEwan, S. R.; Bates, T. C., Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial. Proc. Biol. Sci., 2003, 270(1529), 2147-2150.
43. McMahon, F. J.; Stine, O. C.; Meyers, D. A.; Simpson, S. G.; DePaulo, J. R., Patterns of maternal transmission in bipolar affective disorder. Am. J. Hum. Genet., 1995, 56(6), 1277-1286.
44. Munakata, K.; Iwamoto, K.; Bundo, M.; Kato, T., Mitochondrial DNA 3243A>G mutation and increased expression of LARS2 gene in the brains of patients with bipolar disorder and schizophrenia. Biol. Psychiatry, 2005, 57(5), 525-532.
45. Kazuno, A.-A.; Munakata, K.; Mori, K.; Nanko, S.; Kunugi, H.; Nakamura, K.; Mori, N.; Yamada, K.; Yoshikawa, T.; Kato, N.; Kato, T., Mitochondrial DNA haplogroup analysis in patients with bipolar disorder. Am. J. Med. Genet B, Neuropsychiatr. Genet., 2009, 150B(2), 243-247.
46. Chang, C.-C.; Jou, S.-H.; Lin, T.-T.; Liu, C.-S., Mitochondrial DNA variation and increased oxidative damage in euthymic patients with bipolar disorder. Psychiatry Clin. Neurosci., 2014, 68(7), 551-557.
47. Dubovsky, S. L.; Murphy, J.; Thomas, M.; Rademacher, J., Abnormal intracellular calcium ion concentration in platelets and lymphocytes of bipolar patients. Am. J. Psych., 1992, 149(1), 118-120.
48. Moutsatsou, P.; Tsoporis, J. N.; Salpeas, V.; Bei, E.; Alevizos, B.; Anagnostara, C.; Izhar, S.; Proteau, G.; Rizos, E.; Hatziagelaki, E.; Toumpoulis, I. K.; Rizos, I. K.; Parker, T. G., Peripheral blood lymphocytes from patients with bipolar disorder demonstrate apoptosis and differential regulation of advanced glycation end products and S100B. Clin. Chem. Lab. Med., 2014, 52(7), 999-1007.
49. Barbosa, I. G.; Rocha, N. P.; Assis, F.; Vieira, É. L. M.; Soares, J. C.; Bauer, M. E.; Teixeira, A.L., Monocyte and Lymphocyte Activation in Bipolar Disorder: A New Piece in the Puzzle of Immune Dysfunction in Mood Disorders. Int. J. Neuropsychopharmacol., 2014, 18(1).
50. Schwarz, A.; Schumacher, M.; Pfaff, D.; Schumacher, K.; Jarius, S.; Balint, B.; Wiendl, H.; Haas, J.; Wildemann, B., Fine-tuning of regulatory T cell function: the role of calcium signals and naive regulatory T cells for regulatory T cell deficiency in multiple sclerosis. J. Immunol., 2013, 190(10), 4965-4970.
51. Dubovsky, S. L.; Thomas, M.; Hijazi, A.; Murphy, J., Intracellular calcium signalling in peripheral cells of patients with bipolar affective disorder. Eur. Arch. Psychiatry Clin. Neurosci., 1994, 243(5), 229-234.
52. Washizuka, S.; Kakiuchi, C.; Mori, K.; Tajima, O.; Akiyama, T.; Kato, T., Expression of mitochondria-related genes in lymphoblastoid cells from patients with bipolar disorder. Bipolar Disord., 2005, 7(2), 146-152.
53. Washizuka, S.; Iwamoto, K.; Kazuno, A.-A.; Kakiuchi, C.; Mori, K.; Kametani, M.; Yamada, K.; Kunugi, H.; Tajima, O.; Akiyama, T.; Nanko, S.; Yoshikawa, T.; Kato, T., Association of mitochondrial complex I subunit gene NDUFV2 at 18p11 with bipolar disorder in Japanese and the National Institute of Mental Health pedigrees. Biol. Psychiatry, 2004, 56(7), 483-489.
54. Xu, C.; Li, P. P.; Kennedy, J. L.; Green, M.; Hughes, B.; Cooke, R. G.; Parikh, S. V.; Warsh, J. J., Further support for association of the mitochondrial complex I subunit gene NDUFV2 with bipolar disorder. Bipolar Disord., 2008, 10(1), 105-110.
55. Beech, R. D.; Lowthert, L.; Leffert, J. J.; Mason, P. N.; Taylor, M. M.; Umlauf, S.; Lin, A.; Lee, J. Y.; Maloney, K.; Muralidharan, A.; Lorberg, B.; Zhao, H.; Newton, S. S.; Mane, S.; Epperson, C. N.; Sinha, R.; Blumberg, H.; Bhagwagar, Z., Increased peripheral blood expression of electron transport chain genes in bipolar depression. Bipolar Disord., 2010, 12(8), 813-824.
56. Naydenov, A. V.; MacDonald, M. L.; Ongur, D.; Konradi, C., Differences in lymphocyte electron transport gene expression levels between subjects with bipolar disorder and normal controls in response to glucose deprivation stress. Arch. Gen. Psychiatry, 2007, 64(5), 555-564.
57. Adler, C. M.; Levine, A. D.; DelBello, M. P.; Strakowski, S. M., Changes in Gray Matter Volume in Patients with Bipolar Disorder. Biol. Psychiatry, 2005, 58(2), 151-157.
58. Wallace, D. C., A Mitochondrial Paradigm of Metabolic and Degenerative Diseases, Aging, and Cancer: A Dawn for Evolutionary Medicine. Annu. Rev. Genet., 2005, 39, 359-407.
59. Morris, G.; Maes, M., Mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. Metab. Brain Dis., 2014, 29(1), 19-36.
60. Lucas, K.; Maes, M., Role of the Toll Like receptor(TLR) radical cycle in chronic inflammation: possible treatments targeting the TLR4 pathway. Mol. Neurobiol., 2013, 48(1), 190-204.
61. Brown, N. C.; Andreazza, A. C.; Young, L. T., An updated metaanalysis of oxidative stress markers in bipolar disorder. Psychiatry Res., 2014, 218(1-2), 61-68.
62. Andreazza, A. C.; Wang, J.-F.; Salmasi, F.; Shao, L.; Young, L. T., Specific subcellular changes in oxidative stress in prefrontal cortex from patients with bipolar disorder. J. Neurochem., 2013, 127(4), 552-561.
63. Rajkowska, G.; Halaris, A.; Selemon, L. D., Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol. Psychiatry, 2001, 49(9), 741-752.
64. Javadapour, A.; Malhi, G. S.; Ivanovski, B.; Chen, X.; Wen, W.; Sachdev, P., Increased anterior cingulate cortex volume in bipolar I disorder. Aust. N. Z. J. Psychiatry, 2007, 41(11), 910-916.
65. Singh, M. K.; Chang, K. D.; Chen, M. C.; Kelley, R. G.; Garrett, A.; Mitsunaga, M. M.; Bararpour, L.; Howe, M.; Reiss, A. L.; Gotlib, I. H., Volumetric reductions in the subgenual anterior cingulate cortex in adolescents with bipolar I disorder. Bipolar Disord., 2012, 14(6), 585-596.
66. Kushnareva, Y.; Murphy, A. N.; Andreyev, A., Complex Imediated reactive oxygen species generation: modulation by cytochrome c and NAD(P)+ oxidation-reduction state. Biochem. J., 2002, 368(Pt 2), 545-553.
67. Scola, G.; Kim, H. K.; Young, L. T.; Andreazza, A. C., A fresh look at complex I in microarray data: clues to understanding disease-specific mitochondrial alterations in bipolar disorder. Biol. Psychiatry, 2013, 73(2), e4-e5.
68. Frey, B. N.; Valvassori, S. S.; Réus, G. Z.; Martins, M. R.; Petronilho, F. C.; Bardini, K.; Dal-Pizzol, F.; Kapczinski, F.; Quevedo, J., Effects of lithium and valproate on amphetamineinduced oxidative stress generation in an animal model of mania. J. Psychiatry Neurosci., 2006, 31(5), 326-332.
69. Maurer, I. C.; Schippel, P.; Volz, H.-P., Lithium-induced enhancement of mitochondrial oxidative phosphorylation in human brain tissue. Bipolar Disord., 2009, 11(5), 515-522.
70. Savaş, H. A.; Herken, H.; Yürekli, M.; Uz, E.; Tutkun, H.; Zoroğlu, S. S.; Özen, M. E.; Cengiz, B.; Akyol, Ö., Possible Role of Nitric Oxide and Adrenomedullin in Bipolar Affective Disorder. Neuropsychobiology, 2002, 45(2), 57-61.
71. Savas, H. A.; Gergerlioglu, H. S.; Armutcu, F.; Herken, H.; Yilmaz, H. R.; Kocoglu, E.; Selek, S.; Tutkun, H.; Zoroglu, S. S.; Akyol, O., Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J. Biol. Psychiatry, 2006, 7(1), 51-55.
72. Bolaños, J. P.; Heales, S. J.; Peuchen, S.; Barker, J. E.; Land, J. M.; Clark, J. B., Nitric oxide-mediated mitochondrial damage: a potential neuroprotective role for glutathione. Free Radic. Biol. Med., 1996, 21(7), 995-1001.
73. Horn, T. F. W.; Wolf, G.; Duffy, S.; Weiss, S.; Keilhoff, G.; MacVicar, B. A., Nitric oxide promotes intracellular calcium release from mitochondria in striatal neurons. FASEB J., 2002, 16(12), 1611-1622.
74. Bao, F.; Liu, D., Peroxynitrite generated in the rat spinal cord induces neuron death and neurological deficits. Neuroscience, 2002, 115(3), 839-849.
75. Drechsel, D. A.; Estévez, A. G.; Barbeito, L.; Beckman, J. S., Nitric oxide-mediated oxidative damage and the progressive demise of motor neurons in ALS. Neurotox. Res., 2012, 22(4), 251-264.
76. Parihar, M. S.; Parihar, A.; Villamena, F. A.; Vaccaro, P. S.; Ghafourifar, P., Inactivation of mitochondrial respiratory chain complex I leads mitochondrial nitric oxide synthase to become prooxidative. Biochem. Biophys. Res. Commun., 2008, (4), 761.
77. Morris, G.; Maes, M., A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome. Metab. Brain Dis., 2013, 28(4), 523-540.
78. Morris, G.; Maes, M., Oxidative and Nitrosative Stress and Immune-Inflammatory Pathways in Patients with Myalgic Encephalomyelitis(ME)/Chronic Fatigue Syndrome(CFS). Curr. Neuropharmacol., 2014, 12(2), 168-185.
79. Brietzke, E.; Kapczinski, F., TNF-alpha as a molecular target in bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2008, 32(6), 1355-1361.
80. Vaughan, R. A.; Garcia-Smith, R.; Trujillo, K. A.; Bisoffi, M., Tumor necrosis factor alpha increases aerobic glycolysis and reduces oxidative metabolism in prostate epithelial cells. Prostate, 2013, 73(14), 1538-1546.
81. Vaughan, R. A.; Garcia-Smith, R.; Dorsey, J.; Griffith, J. K.; Bisoffi, M.; Trujillo, K. A., Tumor necrosis factor alpha induces Warburg-like metabolism and is reversed by anti-inflammatory curcumin in breast epithelial cells. Int. J. Cancer, 2013, 133(10), 2504-2510.
82. Palomer, X.; Alvarez-Guardia, D.; Rodríguez-Calvo, R.; Coll, T.; Laguna, J. C.; Davidson, M. M.; Chan, T. O.; Feldman, A. M.; Vázquez-Carrera, M., TNF-alpha reduces PGC-1alpha expression through NF-kappaB and p38 MAPK leading to increased glucose oxidation in a human cardiac cell model. Cardiovasc. Res., 2009, 81(4), 703-712.
83. Ventura-Clapier, R.; Garnier, A.; Veksler, V., Transcriptional control of mitochondrial biogenesis: the central role of PGC-1alpha. Cardiovasc. Res., 2008, 79(2), 208-217.
84. Gergerlioglu, H. S.; Savas, H. A.; Bulbul, F.; Selek, S.; Uz, E.; Yumru, M., Changes in nitric oxide level and superoxide dismutase activity during antimanic treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31(3), 697-702.
85. Selek, S.; Savas, H. A.; Gergerlioglu, H. S.; Bulbul, F.; Uz, E.; Yumru, M., The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J. Affect. Disord., 2008, 107(1-3), 89-94.
86. Karolewicz, B.; Paul, I. A.; Antkiewicz-Michaluk, L., Effect of NOS inhibitor on forced swim test and neurotransmitters turnover in the mouse brain. Pol. J. Pharmacol., 2001, 53(6), 587-596.
87. Ghasemi, M.; Sadeghipour, H.; Mosleh, A.; Sadeghipour, H. R.; Mani, A. R.; Dehpour, A. R., Nitric oxide involvement in the antidepressant-like effects of acute lithium administration in the mouse forced swimming test. Eur. Neuropsychopharmacol., 2008, 18(5), 323-332.
88. Raffa, M.; Barhoumi, S.; Atig, F.; Fendri, C.; Kerkeni, A.; Mechri, A., Reduced antioxidant defense systems in schizophrenia and bipolar I disorder. Prog. Neuropsychopharmocol. Biol. Psychiatry, 2012, 39(2), 371-375.
89. Kuloglu, M.; Ustundag, B.; Atmaca, M.; Canatan, H.; Tezcan, A. E.; Cinkilinc, N., Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem. Funct., 2002, 20(2), 171-175.
90. Maes, M.; Fišar, Z.; Medina, M.; Scapagnini, G.; Nowak, G.; Berk, M., New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology, 2012, 20(3), 127-150.
91. Berk, M.; Copolov, D. L.; Dean, O.; Lu, K.; Jeavons, S.; Schapkaitz, I.; Anderson-Hunt, M.; Bush, A. I., N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial. Biol. Psychiatry, 2008, 64(6), 468-475.
92. Derecki, N. C.; Cronk, J. C.; Kipnis, J., The role of microglia in brain maintenance: implications for Rett syndrome. Trends Immunol., 2013, 34(3), 144-150.
93. Sawada, M.; Kondo, N.; Suzumura, A.; Marunouchi, T., Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res., 1989, 491(2), 394-397.
94. Doganavsargil-Baysal, O.; Cinemre, B.; Aksoy, U. M.; Akbas, H.; Metin, O.; Fettahoglu, C.; Gokmen, Z.; Davran, F., Levels of TNF-α, soluble TNF receptors(sTNFR1, sTNFR2), and cognition in bipolar disorder. Hum. Psychopharmacol., 2013, 28(2), 160-167.
95. Mariappan, N.; Elks, C. M.; Fink, B.; Francis, J., TNF-induced mitochondrial damage: a link between mitochondrial complex I activity and left ventricular dysfunction. Free Radic. Biol. Med., 2009, 46(4), 462-470.
96. Goossens, V.; Stangé, G.; Moens, K.; Pipeleers, D.; Grooten, J., Regulation of tumor necrosis factor-induced, mitochondria-and reactive oxygen species-dependent cell death by the electron flux through the electron transport chain complex I. Antiox. Redox Signal., 1999, 1(3), 285-295.
97. Moe, G. W.; Marin-Garcia, J.; Konig, A.; Goldenthal, M.; Lu, X.; Feng, Q., In vivo TNF-alpha inhibition ameliorates cardiac mitochondrial dysfunction, oxidative stress, and apoptosis in experimental heart failure. Am. J. Physiol. Heart Circ. Physiol., 2004, 287(4), H1813-H1820.
98. Schulze-Osthoff, K.; Bakker, A. C.; Vanhaesebroeck, B.; Beyaert, R.; Jacob, W. A.; Fiers, W., Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. J. Biol.Chem., 1992, 267(8), 5317-5323.
99. Samavati, L.; Lee, I.; Mathes, I.; Lottspeich, F.; Hüttemann, M., Tumor necrosis factor alpha inhibits oxidative phosphorylation through tyrosine phosphorylation at subunit I of cytochrome c oxidase. J. Biol. Chem., 2008, 283(30), 21134-21144.
100. Jia, L.; Kelsey, S. M.; Grahn, M. F.; Jiang, X. R.; Newland, A. C., Increased activity and sensitivity of mitochondrial respiratory enzymes to tumor necrosis factor alpha-mediated inhibition is associated with increased cytotoxicity in drug-resistant leukemic cell lines. Blood, 1996, 87(6), 2401-2410.
101. Gottlieb, E.; Vander Heiden, M. G.; Thompson, C. B., Bcl-x(L) prevents the initial decrease in mitochondrial membrane potential and subsequent reactive oxygen species production during tumor necrosis factor alpha-induced apoptosis. Mol. Cell. Biol., 2000, 20(15), 5680-5689.
102. Li, C.; Liu, Q.; Li, N.; Chen, W.; Wang, L.; Wang, Y.; Yu, Y.; Cao, X., EAPF/Phafin-2, a novel endoplasmic reticulum-associated protein, facilitates TNF-alpha-triggered cellular apoptosis through endoplasmic reticulum-mitochondrial apoptotic pathway. J. Mol. Med., 2008, 86(4), 471-484.
103. Uslu, R.; Bonavida, B., Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both tumor necrosis factor-alpha and cis-diamminedichloroplatinum. Cancer, 1996, 77(4), 725-732.
104. Hennet, T.; Richter, C.; Peterhans, E., Tumour necrosis factoralpha induces superoxide anion generation in mitochondria of L929 cells. Biochem. J., 1993, 289(Pt 2), 587-592.
105. Zell, R.; Geck, P.; Werdan, K.; Boekstegers, P., TNF-alpha and IL-1 alpha inhibit both pyruvate dehydrogenase activity and mitochondrial function in cardiomyocytes: evidence for primary impairment of mitochondrial function. Mol. Cell. Biochem., 1997, 177(1-2), 61-67.
106. Tredget, E. E.; Yu, Y. M.; Zhong, S.; Burini, R.; Okusawa, S.; Gelfand, J. A.; Dinarello, C. A.; Young, V. R.; Burke, J. F., Role of interleukin 1 and tumor necrosis factor on energy metabolism in rabbits. Am. J. Physiol., 1988, 255(6 Pt 1), E760-E768.
107. Tang, K.; Wagner, P. D.; Breen, E. C., TNF-alpha-mediated reduction in PGC-1alpha may impair skeletal muscle function after cigarette smoke exposure. J. Cell. Physiol., 2010, 222(2), 320-327.
108. Remels, A. H. V.; Gosker, H. R.; Schrauwen, P.; Hommelberg, P. P. H.; Sliwinski, P.; Polkey, M.; Galdiz, J.; Wouters, E. F. M.; Langen, R. C. J.; Schols, A. M. W. J., TNF-alpha impairs regulation of muscle oxidative phenotype: implications for cachexia? FASEB J., 2010, 24(12), 5052-5062.
109. Austin, S.; St-Pierre, J., PGC1α and mitochondrial metabolism--emerging concepts and relevance in ageing and neurodegenerative disorders. J. Cell Sci., 2012, 125(Pt 21), 4963-4971.
110. Liang, H.; Ward, W. F., PGC-1alpha: a key regulator of energy metabolism. Adv. Physiol. Educ., 2006, 30(4), 145-151.
111. Guloksuz, S.; Altinbas, K.; Aktas Cetin, E.; Kenis, G.; Bilgic Gazioglu, S.; Deniz, G.; Oral, E. T.; van Os, J., Evidence for an association between tumor necrosis factor-alpha levels and lithium response. J. Affect. Disord., 2012, 143(1-3), 148-152.
112. Struewing, I. T.; Barnett, C. D.; Tang, T.; Mao, C. D., Lithium increases PGC-1alpha expression and mitochondrial biogenesis in primary bovine aortic endothelial cells. FEBS J., 2007, 274(11), 2749-2765.
113. Goldberg, J. F.; Brooks, J. O., 3rd; Kurita, K.; Hoblyn, J. C.; Ghaemi, S. N.; Perlis, R. H.; Miklowitz, D. J.; Ketter, T. A.; Sachs, G. S.; Thase, M. E., Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J. Clin. Psychiatry, 2009, 70(2), 155-162.
114. Ko, G. Y.; Brown-Croyts, L. M.; Teyler, T. J., The effects of anticonvulsant drugs on NMDA-EPSP, AMPA-EPSP, and GABAIPSP in the rat hippocampus. Brain Res. Bull., 1997, 42(4), 297-302.
115. Nonaka, S.; Hough, C. J.; Chuang, D. M., Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptormediated calcium influx. Proc. Natl. Acad. Sci. U. S. A., 1998, 95(5), 2642-2647.
116. Hashimoto, R.; Takei, N.; Shimazu, K.; Christ, L.; Lu, B.; Chuang, D.-M., Lithium induces brain-derived neurotrophic factor and activates TrkB in rodent cortical neurons: an essential step for neuroprotection against glutamate excitotoxicity. Neuropharmacology, 2002, 43(7), 1173-1179.
117. Einat, H.; Yuan, P.; Gould, T. D.; Li, J.; Du, J.; Zhang, L.; Manji, H. K.; Chen, G., The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J. Neurosci., 2003, 23(19), 7311-7316.
118. Michaelis, E. K., Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Prog. Neurobiol., 1998, 54(4), 369-415.
119. Dang, Y.-H.; Ma, X.-C.; Zhang, J.-C.; Ren, Q.; Wu, J.; Gao, C.-G.; Hashimoto, K., Targeting of NMDA Receptors in the Treatment of Major Depression. Curr. Pharm. Des., 2014.
120. Hertz, L.; Song, D.; Li, B.; Du, T.; Xu, J.; Gu, L.; Chen, Y.; Peng, L., Signal Transduction in Astrocytes during Chronic or Acute Treatment with Drugs(SSRIs, Antibipolar Drugs, GABA-ergic Drugs, and Benzodiazepines) Ameliorating Mood Disorders. J. Signal Transduct., 2014, 2014, 593934-593934.
121. Pietruczuk, K.; Jóźwik, A.; Ruckemann-Dziurdzińska, K.; Bryl, E.; Witkowski, J. M., Cytoprotective effect of lithium against spontaneous and induced apoptosis of lymphoid cell line MOLT-4. Folia Histochem. Cytobiol., 2009, 47(4), 639-646.
122. Chen, G.; Zeng, W. Z.; Yuan, P. X.; Huang, L. D.; Jiang, Y. M.; Zhao, Z. H.; Manji, H. K., The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem., 1999, 72(2), 879-882.
123. Shalbuyeva, N.; Brustovetsky, T.; Brustovetsky, N., Lithium desensitizes brain mitochondria to calcium, antagonizes permeability transition, and diminishes cytochrome C release. J. Biol. Chem.., 2007, 282(25), 18057-18068.
124. Moore, G. J.; Bebchuk, J. M.; Wilds, I. B.; Chen, G.; Manji, H. K., Lithium-induced increase in human brain grey matter. Lancet, 2000, 356(9237), 1241-1242.
125. Müller-Oerlinghausen, B.; Felber, W.; Berghöfer, A.; Lauterbach, E.; Ahrens, B., The impact of lithium long-term medication on suicidal behavior and mortality of bipolar patients. Arch. Suicide Res., 2005, 9(3), 307-319.
126. Valvassori, S. S.; Rezin, G. T.; Ferreira, C. L.; Moretti, M.; Gonçalves, C. L.; Cardoso, M. R.; Streck, E. L.; Kapczinski, F.; Quevedo, J., Effects of mood stabilizers on mitochondrial respiratory chain activity in brain of rats treated with damphetamine. J. Psychiatr. Res., 2010, 44(14), 903-909.
127. Huzayyin, A. A.; Andreazza, A. C.; Turecki, G.; Cruceanu, C.; Rouleau, G. A.; Alda, M.; Young, L. T., Decreased global methylation in patients with bipolar disorder who respond to lithium. Int. J. Neuropsychopharmacol., 2014, 17(4), 561-569.
128. Sharma, L. K.; Fang, H.; Liu, J.; Vartak, R.; Deng, J.; Bai, Y., Mitochondrial respiratory complex I dysfunction promotes tumorigenesis through ROS alteration and AKT activation. Hum. Mol. Genet., 2011, 20(23), 4605-4616.
129. Franco, R.; Schoneveld, O.; Georgakilas, A. G.; Panayiotidis, M. I., Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett., 2008, 266(1), 6-11.
130. Banerjee, U.; Dasgupta, A.; Rout, J. K.; Singh, O. P., Effects of lithium therapy on Na+-K+-ATPase activity and lipid peroxidation in bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2012, 37(1), 56-61.
131. de Sousa, R. T.; Zarate, C. A., Jr.; Zanetti, M. V.; Costa, A. C.; Talib, L. L.; Gattaz, W. F.; Machado-Vieira, R., Oxidative stress in early stage Bipolar Disorder and the association with response to lithium. J. Psychiatr. Res., 2014, 50, 36-41.
132. Chen, H.; Dzitoyeva, S.; Manev, H., Effect of valproic acid on mitochondrial epigenetics. Eur. J. Pharmacol., 2012, 690(1-3), 51-59.
133. Washizuka, S.; Ikeda, A.; Kato, N.; Kato, T., Possible relationship between mitochondrial DNA polymorphisms and lithium response in bipolar disorder. Int. J. Neuropsychopharmacol., 2003, 6(4), 421-424.
134. Kazuno, A.-A.; Munakata, K.; Kato, N.; Kato, T., Mitochondrial DNA-dependent effects of valproate on mitochondrial calcium levels in transmitochondrial cybrids. Int. J. Neuropsychopharmacol., 2008, 11(1), 71-78.
135. Matthews, R. T.; Yang, L.; Browne, S.; Baik, M.; Beal, M. F., Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. U.S.A., 1998, 95(15), 8892-8897.
136. Feigin, A.; Kieburtz, K.; Como, P.; Hickey, C.; Claude, K.; Abwender, D.; Zimmerman, C.; Steinberg, K.; Shoulson, I., Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov. Disord., 1996, 11(3), 321-323.
137. Maes, M.; Mihaylova, I.; Kubera, M.; Uytterhoeven, M.; Vrydags, N.; Bosmans, E., Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol. Lett., 2009, 30(4), 462-469.
138. Morris, G.; Anderson, G.; Berk, M.; Maes, M., Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications. Mol. Neurobiol., 2013, 48(3), 883-903.
139. Nierenberg, A. A.; Kansky, C.; Brennan, B. P.; Shelton, R. C.; Perlis, R.; Iosifescu, D. V., Mitochondrial modulators for bipolar disorder: a pathophysiologically informed paradigm for new drug development. Aust. N. Z. J. Psychiatry, 2013, 47(1), 26-42.
140. Tohen, M.; McIntyre, R. S.; Kanba, S.; Fujikoshi, S.; Katagiri, H., Efficacy of olanzapine in the treatment of bipolar mania with mixed features defined by DSM-5. J. Affect. Disord., 2014, 168, 136-141.
141. Nielsen, J.; Kane, J. M.; Correll, C. U., Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disord., 2012, 14(8), 863-869.
142. Tohen, M.; Kanba, S.; McIntyre, R. S.; Fujikoshi, S.; Katagiri, H., Efficacy of olanzapine monotherapy in the treatment of bipolar depression with mixed features. J. Affect. Disord., 2014, 164, 57-62.
143. Nasrallah, H., A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology, 2003, 28 Suppl 1, 83-96.
144. Citrome, L.; Holt, R. I. G.; Walker, D. J.; Hoffmann, V. P., Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder. Clin. Drug Investig., 2011, 31(7), 455-482.
145. Hroudova, J.; Fisar, Z., Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers. Neuro Endocrinol. Lett., 2010, 31(3), 336-342.
146. Agostinho, F. R.; Réus, G. Z.; Stringari, R. B.; Ribeiro, K. F.; Ferreira, G. K.; Jeremias, I. C.; Scaini, G.; Rezin, G. T.; Streck, E. L.; Quevedo, J., Olanzapine plus fluoxetine treatment alters mitochondrial respiratory chain activity in the rat brain. Acta Neuropsych., 2011, 23(6), 282-291.
147. Burkhardt, C.; Kelly, J. P.; Lim, Y. H.; Filley, C. M.; Parker, W. D., Jr., Neuroleptic medications inhibit complex I of the electron transport chain. Ann. Neurol., 1993, 33(5), 512-517.
148. Ji, B.; La, Y.; Gao, L.; Zhu, H.; Tian, N.; Zhang, M.; Yang, Y.; Zhao, X.; Tang, R.; Ma, G.; Zhou, J.; Meng, J.; Ma, J.; Zhang, Z.; Li, H.; Feng, G.; Wang, Y.; He, L.; Wan, C., A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications. J. Proteome Res., 2009, 8(7), 3633-3641.
149. Kim, Y. J.; Ko, H. H.; Han, E. S.; Lee, C. S., Lamotrigine inhibition of rotenone-or 1-methyl-4-phenylpyridinium-induced mitochondrial damage and cell death. Brain Res. Bull., 2007, 71(6), 633-640.
150. Tufan, K.; Oztanir, N.; Ofluoglu, E.; Ozogul, C.; Uzum, N.; Dursun, A.; Pasaoglu, H.; Pasaoglu, A., Ultrastructure protection and attenuation of lipid peroxidation after blockade of presynaptic release of glutamate by lamotrigine in experimental spinal cord injury. Neurosurg. Focus, 2008, 25(5), E6-E6.
151. Xu, H.; Wang, H.; Zhuang, L.; Yan, B.; Yu, Y.; Wei, Z.; Zhang, Y.; Dyck, L. E.; Richardson, S. J.; He, J.; Li, X.; Kong, J.; Li, X.-M., Demonstration of an anti-oxidative stress mechanism of quetiapine: implications for the treatment of Alzheimer's disease. FEBS J., 2008, 275(14), 3718-3728.
152. Post, R. M.; Altshuler, L. L.; Frye, M. A.; Suppes, T.; Rush, A. J.; Keck, P. E., Jr.; McElroy, S. L.; Denicoff, K. D.; Leverich, G. S.; Kupka, R.; Nolen, W. A., Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord., 2001, 3(5), 259-265.
153. van der Loos, M. L. M.; Mulder, P.; Hartong, E. G. T. M.; Blom, M. B. J.; Vergouwen, A. C.; van Noorden, M. S.; Timmermans, M. A.; Vieta, E.; Nolen, W. A., Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disord., 2011, 13(1), 111-117.
154. Tohen, M.; Chengappa, K. N. R.; Suppes, T.; Zarate, C. A., Jr.; Calabrese, J. R.; Bowden, C. L.; Sachs, G. S.; Kupfer, D. J.; Baker, R. W.; Risser, R. C.; Keeter, E. L.; Feldman, P. D.; Tollefson, G. D.; Breier, A., Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch. Gen. Psychiatry, 2002, 59(1), 62-69.
155. Fountoulakis, K. N.; Kasper, S.; Andreassen, O.; Blier, P.; Okasha, A.; Severus, E.; Versiani, M.; Tandon, R.; Möller, H.-J.; Vieta, E., Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry. Eur. Arch. Psychiatry Clin. Neurosci., 2012, 262 Suppl 1, 1-48.
156. Rendell, J. M.; Gijsman, H. J.; Bauer, M. S.; Goodwin, G. M.; Geddes, G. R., Risperidone alone or in combination for acute mania. Cochrane Database Syst. Rev., 2006, 1, CD004043.